HCPCS Code Descriptor:
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
61314-0326-10, 61314-0318-01, 61314-0318-10, 61314-0326-01
Oncology Biosimilar Colony Stimulating Factor
Route of Administration:
ZARXIO is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Sandoz and administered via the Injection route of administration. The Q Code: Q5101 is aligned to the drug ZARXIO.
Zarxio (filgrastim) is an artificial version of a natural substance that is made in your body and is used to aid the production of white blood cells. Zarxio is administered via subcutaneous injection or an intravenous infusion for roughly 15 to 30 minutes. Zarxio is a biosimilar to its reference product Neupogen (J1442). Patient assistance programs for this medication are offered through Sandoz.